Cellebrite DI Ltd 6-K, filed Nov 14, 2023
Cellebrite DI Ltd. (CLBT)
About this 6-K
Cellebrite DI Ltd filed this 6-K on November 14, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of November, 2023
Commission File Number 001-40772
Cellebrite DI Ltd.
(Translation of registrant’s name into English)
94 Shlomo Shmelzer Road
Petah Tikva 4970602, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On November 14, 2023, Cellebrite DI Ltd. (the “Registrant” or “Cellebrite”) issued a press release titled “Cellebrite Announces Third-Quarter 2023 Results.” A copy of this press release is furnished as Exhibit 99.1 herewith.
The GAAP financial statements tables contained in the press release attached to this report on Form 6-K are incorporated by reference into the Registrant’s registration statements on Form S-8 (File No. 333-260878) and Form F-3 (File No. 333-259826).
1
EXHIBIT INDEX
| Exhibit | Description | |
| 99.1 | Press release titled “Cellebrite Announces Third-Quarter 2023 Results” (furnished herewith). |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cellebrite DI Ltd. | ||
| Date: November 14, 2023 | By: | /s/ Dana Gerner |
| Dana Gerner | ||
| Chief Financial Officer | ||
3
Exhibit 99.1
Cellebrite Announces Third-Quarter 2023 Results
Record revenue of $84.2 million, 17% year-over-year increase primarily due to
32% growth in subscription revenue;
Record ARR of $295.2 million, up 27% year-over-year;
Record adjusted EBITDA of $20.8 million, 24.7% Adjusted EBITDA margin;
Company Increases 2023 ARR and Adjusted EBITDA Outlook, and
Raises Mid-Point for Expected 2023 Revenue Range
TYSONS CORNER, VA and PETAH TIKVA, ISRAEL, November 14, 2023 – Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence (“DI”) solutions for the public and private sectors, today announced financial results for the three and nine months ending September 30, 2023.
“I am pleased with Cellebrite’s third-quarter 2023 performance, which demonstrates continued business momentum and meaningful strategic progress,” said Yossi Carmil, Cellebrite’s CEO. “Against the backdrop of a healthy demand environment, we reported record quarterly revenue, ARR and adjusted EBITDA due in large part to the strong traction we are generating within the digital forensic units and investigative units of our law enforcement customers. We move into the final quarter of the year with a compelling value proposition, attractive prospects to grow our wallet share with customers, and an increasingly efficient cost structure that supports ongoing profit improvement. These dynamics are reflected in our updated outlook for 2023.”
Third Quarter 2023 Financial Highlights
| ● | Annual Recurring Revenue (ARR) of $295.2 million, up 27% year-over-year |
| ● | Revenue of $84.2 million, up 17% year-over-year |
| ● | Subscription revenue was $73.3 million, a 32% year-over-year increase |
| ● | Recurring revenue dollar-based net retention rate of 125% |
| ● | GAAP gross profit and gross margin of $71.3 million and 84.7%, respectively; Non-GAAP gross profit and gross profit margin of $71.7 million and 85.2%, respectively |
| ● | GAAP net profit of $6.5 million; Non-GAAP net income of $21.3 million |
| ● | GAAP diluted earnings per share of $0.03; Non-GAAP diluted earnings per share of $0.09 |
| ● | Adjusted EBITDA and adjusted EBITDA margin of $20.8 million and 24.7%, respectively |
Third-Quarter 2023 and Recent Digital Intelligence Highlights
Team
| ● | In a separate announcement today, Cellebrite appointed Marcus Jewell as Global Chief Revenue Officer (CRO), a newly created role, effective November 15, 2023. Mr. Jewell brings to Cellebrite over 25 years of experience in senior-level sales and management, having served as CRO at fast-growing, successful technology companies such as Juniper Networks, Brocade Communications and others. |
Go-to-Market
| ● | Cellebrite closed 25 large deals in the third quarter, each valued at $500,000 or more. Notable third-quarter 2023 deals included: |
| o | Due to the differentiated capabilities of Cellebrite’s Premium solution, a large U.S. Federal agency significantly increased its Premium footprint. As a result, Cellebrite’s ARR at this account grew by over 80% to $6.5 million. |
| o | Cellebrite broadened its relationship with a major U.S. state police department, which licensed Pathfinder and Premium as a Service to help it expedite cases involving digital evidence. This deal increased ARR in this account by 5x to $900,000. |
| o | One of the largest police departments in the U.S. was an early adopter of Smart Search and went live with Smart Search in the third quarter as part of a deal that increased Cellebrite’s ARR by over 30% to over $650,000. |
| o | In the private sector, Cellebrite continued to close new deals for Endpoint Inspector Mobile, which is helping to establish this offering as a leading internal investigation solution for consent-based, mobile data collection involving employees outside of the office. Cellebrite also expanded its relationship with a leading nationwide eDiscovery company for its on-premise offerings, increasing ARR at this account by 20% to $600,000. |
| ● | On November 13, 2023, Cellebrite published critical insights from its 2024 Industry Trends Survey for the Public Sector. The survey findings revealed the urgent need for agencies to digitally transform key workflows to address severe staffing shortages and a growing volume of evidence. |
| ● | On October 18, 2023, Cellebrite announced the unveiling of a cutting-edge website and Learning Management System within its customer portal, MyCellebrite. |
| ● | In mid-October, Cellebrite sponsored and participated in the 2023 International Association of Chiefs of Police (IACP) Annual Conference and Exposition in San Diego, California. |
Innovation
| ● | On November 9, 2023, Cellebrite announced the release of Mobile Ultra, for mobile device investigations to the private sector. An all-in-one application, Mobile Ultra surfaces facts quickly and accelerates the collection, extractions and reporting process during corporate investigations. |
| ● | On November 8, 2023, Cellebrite announced Cellebrite Smart Search, a new SaaS-based solution that securely automates the collection and review of publicly available online data. The addition of Cellebrite Smart Search broadens the range of high-value investigative tools within the Cellebrite portfolio. Built specifically for investigators, Smart Search collects all publicly available online data on a desired individual or organization and surfaces the most relevant information, quickly generating a standardized, shareable report for stakeholders. |
| ● | On August 21, 2023, Cellebrite introduced Endpoint Mobile Now, a new SaaS offering for corporate investigations and eDiscovery, the Company’s first SaaS solution for private sector customers. |
Supplemental financial information can be found on the Investor Relations section of our website at https://investors.cellebrite.com/financial-information/quarterly-results.
Financial Outlook
“In the third quarter of 2023, meaningful gross margin improvement and disciplined spending enabled us to convert solid revenue growth into outstanding profitability and excellent free cash flow,” stated Dana Gerner, Chief Financial Officer of Cellebrite. “Our success in expanding existing customer relationships in recent quarters, a healthy sales pipeline for the fourth quarter and prudent spending focused on key R&D and go-to-market initiatives underpin our expectations for a strong, productive finish to 2023. With revenue trending toward the upper half of our prior full-year 2023 expectations, we have raised our 2023 ARR range to better reflect our near-term sales prospects and we have increased our 2023 adjusted EBITDA range above our prior outlook due to solid revenue growth, a strong gross margin performance, greater operational efficiencies and favorable changes in foreign currency. We believe that our continued progress in executing against our strategic priorities over the coming months will enable us to sustain our momentum into next year.”
2
The Company’s updated 2023 expectations are as follows:
| Prior Expectations | Updated Expectations | |||
| (as of August 8, 2023) | (as of November 14, 2023) | |||
| 2023 Revenue | $310 million - $320 million | $315 million - $320 million | ||
| Growth over 2022 | 15% - 18% | 16% - 18% | ||
| December 2023 ARR | $303 million - $313 million | $310 million - $315 million | ||
| Growth over 2022 | 22% - 26% | 25% - 27% | ||
| 2023 Adjusted EBITDA | $39 million - $44 million | $50 million - $55 million | ||
| 2023 Adjusted EBITDA margin | 13% - 14% | 16% - 17% |
Conference Call Information
Cellebrite will host a live conference call and webcast later this morning to review the Company’s financial results for the third quarter of 2023 and discuss its full-year 2023 outlook. Pertinent details include:
| Date: | Tuesday, November 14, 2023 | |
| Time: | 8:30 a.m. ET | |
| Call-In Number: | 203-518-9848 | |
| Conference ID: | CLBTQ323 | |
| Event URL: | https://investors.cellebrite.com/events/event-details/cellebrite-q3-2023-results-investor-call-webcast | |
| Webcast URL: | https://edge.media-server.com/mmc/p/nd73hvhn |
In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company’s investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results. A transcript of the call will be added to this page along with access to the replay of the call later in the day.
Non-GAAP Financial Information and Key Performance Indicators
This press release includes non-GAAP financial measures. Cellebrite believes that the use of non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating income margin, non-GAAP net income, non-GAAP EPS, adjusted EDITDA and adjusted EBITDA margin is helpful to investors. These measures, which the Company refers to as our non-GAAP financial measures, are not prepared in accordance with GAAP.
The Company believes that the non-GAAP financial measures provide a more meaningful comparison of its operational performance from period to period, and offer investors and management greater visibility to the underlying performance of its business. Mainly:
| ● | Share-based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company’s non-cash expenses; |
| ● | Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the acquisition, and acquisition-related expenses are unrelated to current operations and neither are comparable to the prior period nor predictive of future results; |
3
| ● | To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income; |
| ● | Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to our underlying performance and make period-to-period comparisons more challenging; and |
| ● | Financial instruments are remeasured according to GAAP and vary for many reasons that are often unrelated to the Company’s current operations and affect financial income. |
Each of our non-GAAP financial measures is an important tool for financial and operational decision making and for evaluating our own operating results over different periods of time. The non-GAAP financial measures do not represent our financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net income or any other performance measures derived in accordance with GAAP. Non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may have a material impact on our reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, significant recurring expenses in our business and an important part of the compensation provided to our employees. In addition, the amortization of intangible assets is expected recurring expense over the estimated useful life of the underlying intangible asset and acquisition-related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchange rates may fluctuate from one period to another, and the Company does not estimate movements in foreign currencies.
A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also available on our website at https://investors.cellebrite.com.
In regard to forward-looking non-GAAP guidance, we are not able to reconcile the forward-looking Adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, fair value movements, share-based payments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items.
Key Performance Indicators
This press release also includes key performance indicators, including annual recurring revenue and dollar-based retention rate.
Annual recurring revenue (“ARR”) is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12. The annualized value of contracts is a legal and contractual determination made by assessing the contractual terms with our customers. The annualized value of maintenance contracts is not determined by reference to historical revenue, deferred revenue or any other GAAP financial measure over any period. ARR is not a forecast of future revenues, which can be impacted by contract start and end dates and renewal rates.
4
Dollar-based net retention rate (“NRR”) is calculated by dividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.
About Cellebrite
Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com and https://investors.cellebrite.com.
Note: References to our website and the websites of third parties mentioned in this press release are inactive textual references only, and information contained therein or connected thereto is not incorporated into this press release.
Caution Regarding Forward Looking Statements
This document includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, the following: estimated financial information for fiscal year 2023 and certain statements related to moving into the final quarter of the year with a compelling value proposition, attractive prospects to grow our wallet share with customers, and an increasingly efficient cost structure that supports ongoing profit improvement; our expectations for a strong, productive finish to 2023; revenue trending toward the upper half of our prior full-year 2023 expectations; and our belief that our continued progress in executing against our strategic priorities over the coming months will enable us to sustain our momentum into next year. Such forward-looking statements including those with respect to 2023 revenue, annual recurring revenue (ARR), adjusted EBITDA, operating profitability and earnings as well as commentary associated with future performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel-Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on April 27, 2023 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
5
Contacts:
Investors Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760
Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910
6
Cellebrite DI Ltd.
Third Quarter 2023 Results Summary
(U.S Dollars in thousands)
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Revenue | 84,179 | 71,675 | 232,097 | 196,633 | ||||||||||||
| Gross profit | 71,301 | 57,141 | 193,782 | 158,018 | ||||||||||||
| Gross margin | 84.7 | % | 79.7 | % | 83.5 | % | 80.4 | % | ||||||||
| Operating income (loss) | 13,479 | (1,085 | ) | 18,238 | (8,630 | ) | ||||||||||
| Operating margin | 16.0 | % | (1.5 | )% | 7.9 | % | (4.4 | )% | ||||||||
| Net (loss) income | 6,500 | 25,092 | (66,453 | ) | 113,727 | |||||||||||
| Cash flow from operating activities | 29,179 | (556 | ) | 58,231 | (15,166 | ) | ||||||||||
| Non-GAAP Financial Data: | ||||||||||||||||
| Operating income | 19,252 | 3,412 | 34,300 | 5,110 | ||||||||||||
| Operating margin | 22.9 | % | 4.8 | % | 14.8 | % | 2.6 | % | ||||||||
| Net income | 21,313 | 2,974 | 38,927 | 4,369 | ||||||||||||
| Adjusted EBITDA | 20,792 | 5,053 | 39,220 | 9,792 | ||||||||||||
| Adjusted EBITDA margin | 24.7 | % | 7.0 | % | 16.9 | % | 5.0 | % | ||||||||
7
Cellebrite DI Ltd.
Condensed Consolidated Balance Sheets
(U.S. Dollars in thousands)
| September 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| (Unaudited) | (Audited) | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 137,066 | $ | 87,645 | ||||
| Short-term deposits | 80,359 | 51,335 | ||||||
| Marketable securities | 46,315 | 44,643 | ||||||
| Trade receivables (net of allowance for credit losses of $680 and $1,904 as of September 30, 2023 and December 31, 2022, respectively) | 69,559 | 78,761 | ||||||
| Prepaid expenses and other current assets | 24,476 | 17,085 | ||||||
| Contract acquisition costs | 5,325 | 6,286 | ||||||
| Inventories | 11,210 | 10,176 | ||||||
| Total current assets | 374,310 | 295,931 | ||||||
| Non-current assets | ||||||||
| Other non-current assets | 7,572 | 1,731 | ||||||
| Marketable securities | 19,494 | 22,125 | ||||||
| Deferred tax assets, net | 9,601 | 12,511 | ||||||
| Property and equipment, net | 15,274 | 17,259 | ||||||
| Intangible assets, net | 11,155 | 11,254 | ||||||
| Goodwill | 26,829 | 26,829 | ||||||
| Operating lease right-of-use assets, net | 12,707 | 15,653 | ||||||
| Total non-current assets | 102,632 | 107,362 | ||||||
| Total assets | $ | 476,942 | $ | 403,293 | ||||
| Liabilities and shareholders’ equity | ||||||||
| Current Liabilities | ||||||||
| Trade payables | $ | 7,985 | $ | 4,612 | ||||
| Other accounts payable and accrued expenses | 43,494 | 45,453 | ||||||
| Deferred revenues | 170,659 | 152,709 | ||||||
| Operating lease liabilities | 4,700 | 5,003 | ||||||
| Total current liabilities | 226,838 | 207,777 | ||||||
| Long-term liabilities | ||||||||
| Other long term liabilities | 5,080 | 5,394 | ||||||
| Deferred revenues | 47,596 | 42,173 | ||||||
| Restricted Sponsor Shares liability | 40,272 | 17,532 | ||||||
| Price Adjustment Shares liability | 67,560 | 26,184 | ||||||
| Warrant liability | 44,332 | 20,015 | ||||||
| Operating lease liabilities | 7,322 | 10,353 | ||||||
| Total long-term liabilities | 212,162 | 121,651 | ||||||
| Total liabilities | $ | 439,000 | $ | 329,428 | ||||
| Shareholders’ equity | ||||||||
| Share capital | *) | *) | ||||||
| Additional paid-in capital | (95,155 | ) | (125,624 | ) | ||||
| Treasury share, NIS 0.00001 par value; 41,776 ordinary shares | (85 | ) | (85 | ) | ||||
| Accumulated other comprehensive income | 392 | 331 | ||||||
| Retained earnings | 132,790 | 199,243 | ||||||
| Total shareholders’ equity | 37,942 | 73,865 | ||||||
| Total liabilities and shareholders’ equity | $ | 476,942 | $ | 403,293 | ||||
| *) | Less than 1 USD |
8
Cellebrite DI Ltd.
Condensed Consolidated Statements of Income (loss)
(U.S Dollars in thousands, except share and per share data)
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Revenue: | ||||||||||||||||
| Subscription services | $ | 54,150 | $ | 39,385 | $ | 152,029 | $ | 109,772 | ||||||||
| Term-license | 19,130 | 16,209 | 49,739 | 43,862 | ||||||||||||
| Total subscription | 73,280 | 55,594 | 201,768 | 153,634 | ||||||||||||
| Other non-recurring | 4,185 | 7,407 | 9,075 | 17,707 | ||||||||||||
| Professional services | 6,714 | 8,674 | 21,254 | 25,292 | ||||||||||||
| Total revenue | 84,179 | 71,675 | 232,097 | 196,633 | ||||||||||||
| Cost of revenue: | ||||||||||||||||
| Subscription services | 4,602 | 5,082 | 14,040 | 13,194 | ||||||||||||
| Term-license | 4 | 7 | 6 | 375 | ||||||||||||
| Total subscription | 4,606 | 5,089 | 14,046 | 13,569 | ||||||||||||
| Other non-recurring | 3,515 | 4,108 | 9,422 | 9,606 | ||||||||||||
| Professional services | 4,757 | 5,337 | 14,847 | 15,440 | ||||||||||||
| Total cost of revenue | 12,878 | 14,534 | 38,315 | 38,615 | ||||||||||||
| Gross profit | $ | 71,301 | $ | 57,141 | $ | 193,782 | $ | 158,018 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 20,451 | 21,635 | 62,635 | 60,886 | ||||||||||||
| Sales and marketing | 26,873 | 25,567 | 81,219 | 73,718 | ||||||||||||
| General and administrative | 10,498 | 11,024 | 31,690 | 32,044 | ||||||||||||
| Total operating expenses | $ | 57,822 | $ | 58,226 | $ | 175,544 | $ | 166,648 | ||||||||
| Operating income (loss) | $ | 13,479 | $ | (1,085 | ) | $ | 18,238 | $ | (8,630 | ) | ||||||
| Financial (expense) income, net | (6,630 | ) | 25,422 | (81,456 | ) | 120,288 | ||||||||||
| Income (loss) before tax | 6,849 | 24,337 | (63,218 | ) | 111,658 | |||||||||||
| Tax expense (income) | 349 | (755 | ) | 3,235 | (2,069 | ) | ||||||||||
| Net income (loss) | $ | 6,500 | $ | 25,092 | $ | (66,453 | ) | $ | 113,727 | |||||||
| Earnings (loss) per share | ||||||||||||||||
| Basic | 0.03 | 0.13 | (0.35 | ) | 0.60 | |||||||||||
| Diluted | 0.03 | 0.13 | (0.35 | ) | 0.56 | |||||||||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic | 191,567,601 | 183,275,256 | 188,697,934 | 181,931,507 | ||||||||||||
| Diluted | 204,394,330 | 193,188,295 | 188,697,934 | 194,967,665 | ||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Unrealized (loss) income on hedging transactions | (85 | ) | 760 | (59 | ) | (2,147 | ) | |||||||||
| Unrealized income (loss) on marketable securities | 87 | (260 | ) | 213 | (546 | ) | ||||||||||
| Currency translation adjustments | 873 | (265 | ) | (93 | ) | 547 | ||||||||||
| Total other comprehensive income (loss), net of tax | 875 | 235 | 61 | (2,146 | ) | |||||||||||
| Total other comprehensive income (loss) | $ | 7,375 | $ | 25,327 | $ | (66,392 | ) | $ | 111,581 | |||||||
9
Cellebrite DI Ltd.
Condensed Consolidated Statements of Cash Flow
(U.S Dollars in thousands, except share and per share data)
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Cash flow from operating activities: | ||||||||||||||||
| Net income (loss) | $ | 6,500 | $ | 25,092 | $ | (66,453 | ) | $ | 113,727 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||
| Share based compensation, RSUs and ESPP benefit | 4,881 | 3,458 | 13,938 | 9,921 | ||||||||||||
| Amortization of premium, discount and accrued interest on marketable securities | (337 | ) | (109 | ) | (798 | ) | (147 | ) | ||||||||
| Depreciation and amortization | 2,380 | 2,305 | 7,396 | 6,674 | ||||||||||||
| Interest income from short term deposits | (1,845 | ) | (167 | ) | (4,242 | ) | (366 | ) | ||||||||
| Deferred income taxes | 2,373 | (489 | ) | 2,835 | (2,331 | ) | ||||||||||
| Remeasurement of warrant liability | 2,054 | (5,817 | ) | 24,317 | (36,838 | ) | ||||||||||
| Remeasurement of Restricted Sponsor Shares | 2,647 | (6,449 | ) | 22,740 | (28,561 | ) | ||||||||||
| Remeasurement of Price Adjustment Shares liabilities | 4,779 | (12,825 | ) | 41,376 | (54,431 | ) | ||||||||||
| (Increase) decrease in trade receivables | (8,779 | ) | (23,377 | ) | 9,338 | (24,127 | ) | |||||||||
| Increase in deferred revenue | 13,312 | 18,071 | 23,867 | 20,013 | ||||||||||||
| (Increase) decrease in other non-current assets | (4,779 | ) | — | (5,841 | ) | 133 | ||||||||||
| Increase in prepaid expenses and other current assets | (1,412 | ) | (2,191 | ) | (7,036 | ) | (1,261 | ) | ||||||||
| Changes in operating lease assets | 1,438 | — | 4,138 | — | ||||||||||||
| Changes in operating lease liability | (1,564 | ) | — | (4,526 | ) | — | ||||||||||
| Increase in inventories | (396 | ) | (1,247 | ) | (1,038 | ) | (2,868 | ) | ||||||||
| Increase (decrease) in trade payables | 2,989 | 1,197 | 3,370 | (4,576 | ) | |||||||||||
| Increase (decrease) in other accounts payable and accrued expenses | 4,904 | 2,370 | (4,837 | ) | (6,793 | ) | ||||||||||
| Increase (decrease) in other long-term liabilities | 33 | (378 | ) | (314 | ) | (3,335 | ) | |||||||||
| Net cash provided by (used in) operating activities | 29,178 | (556 | ) | 58,230 | (15,166 | ) | ||||||||||
| Cash flows from investing activities: | ||||||||||||||||
| Purchases of property and equipment | (1,082 | ) | (1,630 | ) | (2,971 | ) | (5,506 | ) | ||||||||
| Purchase of Intangible assets | — | (400 | ) | — | (400 | ) | ||||||||||
| Investment in marketable securities | (15,000 | ) | (19,426 | ) | (42,005 | ) | (80,111 | ) | ||||||||
| Proceeds from maturity of marketable securities | 14,550 | 9,660 | 44,057 | 14,832 | ||||||||||||
| Investment in short term deposits | (10,000 | ) | — | (64,000 | ) | (25,000 | ) | |||||||||
| Redemption of short term deposits | 637 | — | 39,218 | 42,397 | ||||||||||||
| Net cash used in investing activities | (10,895 | ) | (11,796 | ) | (25,701 | ) | (53,788 | ) | ||||||||
| Cash flows from financing activities: | ||||||||||||||||
| Exercise of options to shares | 8,130 | 6,618 | 15,315 | 11,301 | ||||||||||||
| Exercise of public warrants | — | — | — | 5 | ||||||||||||
| Proceeds from Employee Share Purchase Plan, net | 686 | 680 | 1,920 | 680 | ||||||||||||
| Net cash provided by financing activities | 8,816 | 7,298 | 17,235 | 11,986 | ||||||||||||
| Net increase (decrease) in cash and cash equivalents | 27,099 | (5,054 | ) | 49,764 | (56,968 | ) | ||||||||||
| Net effect of Currency Translation on cash and cash equivalents | (535 | ) | (2,065 | ) | (343 | ) | (4,439 | ) | ||||||||
| Cash and cash equivalents at beginning of period | 110,502 | 91,685 | 87,645 | 145,973 | ||||||||||||
| Cash and cash equivalents at end of period | $ | 137,066 | $ | 84,566 | $ | 137,066 | $ | 84,566 | ||||||||
| Supplemental cash flow information: | ||||||||||||||||
| Income taxes paid | $ | 673 | $ | 1,437 | $ | 9,200 | $ | 5,326 | ||||||||
| Non-cash activities | ||||||||||||||||
| Purchase of property and equipment | $ | — | $ | 79 | $ | — | $ | 142 | ||||||||
Purchase of Intangible assets | $ | — | $ | 171 | $ | — | $ | 171 | ||||||||
10
Cellebrite DI Ltd.
Reconciliation of GAAP to Non-GAAP Financial Information
(U.S Dollars in thousands, except share and per share data)
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Cost of revenues | $ | 12,878 | $ | 14,534 | $ | 38,315 | $ | 38,615 | ||||||||
| Less: | ||||||||||||||||
| Share based compensation | 435 | 355 | 1,235 | 940 | ||||||||||||
| Acquisition related costs | 12 | — | 39 | — | ||||||||||||
| Non-GAAP cost of revenues | $ | 12,431 | $ | 14,179 | $ | 37,041 | $ | 37,675 | ||||||||
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Gross profit | $ | 71,301 | $ | 57,141 | $ | 193,782 | $ | 158,018 | ||||||||
| Share based compensation | 435 | 355 | 1,235 | 940 | ||||||||||||
| Acquisition related costs | 12 | — | 39 | — | ||||||||||||
| Non-GAAP gross profit | $ | 71,748 | $ | 57,496 | $ | 195,056 | $ | 158,958 | ||||||||
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Operating expenses | $ | 57,822 | $ | 58,226 | $ | 175,544 | $ | 166,648 | ||||||||
| Less: | ||||||||||||||||
| Issuance expenses | — | — | (345 | ) | — | |||||||||||
| Share based compensation | 4,446 | 3,102 | 12,703 | 8,980 | ||||||||||||
| Amortization of intangible assets | 840 | 664 | 2,476 | 1,992 | ||||||||||||
| Acquisition related costs | 40 | 375 | (46 | ) | 1,827 | |||||||||||
| Non-GAAP operating expenses | $ | 52,496 | $ | 54,085 | $ | 160,756 | $ | 153,849 | ||||||||
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Operating income (loss) | $ | 13,479 | $ | (1,085 | ) | $ | 18,238 | $ | (8,630 | ) | ||||||
| Issuance expenses | — | — | (345 | ) | — | |||||||||||
| Share based compensation | 4,881 | 3,458 | 13,938 | 9,921 | ||||||||||||
| Amortization of intangible assets | 840 | 664 | 2,476 | 1,992 | ||||||||||||
| Acquisition related costs | 52 | 375 | (7 | ) | 1,827 | |||||||||||
| Non-GAAP operating income | $ | 19,252 | $ | 3,412 | $ | 34,300 | $ | 5,110 | ||||||||
11
Cellebrite DI Ltd.
Reconciliation of GAAP to Non-GAAP Financial Information
(U.S Dollars in thousands, except share and per share data)
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Net (loss) income | $ | 6,500 | $ | 25,092 | $ | (66,453 | ) | $ | 113,727 | |||||||
| Issuance expenses | — | — | (345 | ) | — | |||||||||||
| One time tax income | — | (543 | ) | — | (2,368 | ) | ||||||||||
| Share based compensation | 4,881 | 3,458 | 13,938 | 9,921 | ||||||||||||
| Amortization of intangible assets | 840 | 664 | 2,476 | 1,992 | ||||||||||||
| Acquisition related costs | 52 | 375 | (7 | ) | 1,827 | |||||||||||
| Tax expense (income) | (440 | ) | (981 | ) | 885 | (900 | ) | |||||||||
| Finance expense (income) from financial derivatives | 9,480 | (25,091 | ) | 88,433 | (119,830 | ) | ||||||||||
| Non-GAAP net income | $ | 21,313 | $ | 2,974 | $ | 38,927 | $ | 4,369 | ||||||||
| Non-GAAP Earnings per share: | ||||||||||||||||
| Basic | $ | 0.10 | $ | 0.02 | $ | 0.19 | $ | 0.02 | ||||||||
| Diluted | $ | 0.09 | $ | 0.01 | $ | 0.18 | $ | 0.02 | ||||||||
| Weighted average shares outstanding: | ||||||||||||||||
| Basic | 191,567,601 | 183,275,256 | 188,697,934 | 181,931,507 | ||||||||||||
| Diluted | 204,394,330 | 193,188,295 | 202,899,131 | 194,967,665 | ||||||||||||
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Net (loss) income | $ | 6,500 | $ | 25,092 | $ | (66,453 | ) | $ | 113,727 | |||||||
| Issuance expenses | — | — | (345 | ) | — | |||||||||||
| Financial expense (income), net | 6,630 | (25,422 | ) | 81,456 | (120,288 | ) | ||||||||||
| Tax expense (income) | 349 | (755 | ) | 3,235 | (2,069 | ) | ||||||||||
| Share based compensation | 4,881 | 3,458 | 13,938 | 9,921 | ||||||||||||
| Amortization of intangible assets | 840 | 664 | 2,476 | 1,992 | ||||||||||||
| Acquisition related costs | 52 | 375 | (7 | ) | 1,827 | |||||||||||
| Depreciation expenses | 1,540 | 1,641 | 4,920 | 4,682 | ||||||||||||
| Adjusted EBITDA | $ | 20,792 | $ | 5,053 | $ | 39,220 | $ | 9,792 | ||||||||
12